Healthcare and Pharmaceutical Sector

AstraZeneca lost more than £17 billion in market value after reports emerged of merger discussions with Bristol Myers Squibb to create a $400 billion entity. The sell-off pushed AstraZeneca's market capitalization down to £178 billion, ceding its rank as the UK's second-most valuable listed company to Shell. Investors reacted negatively to taking on BMS's impending patent cliffs, including revenue declines for Opdivo before 2030, which threatens AstraZeneca's target of $80 billion in annual sales by 2030 compared to $59 billion last year. The news continues coverage from August 3 detailing the proposed combination. While bulls argue the deal expands US commercial infrastructure and cancer portfolios, critics at Bloomberg Intelligence cite pipeline disruption risks. US antitrust regulators would heavily scrutinize overlapping oncology assets. This reading would be falsified if AstraZeneca's stock recovers sharply following formal deal terms.

CapVest Partners-backed Curium agreed to acquire rival US radiopharmaceutical maker Lantheus in an all-cash transaction valued up to nearly $8 billion. Under the terms, Curium will pay $102.50 per share in cash upon closing, alongside non-transferable contingent value rights worth up to an additional $12.00 per share if commercial milestones are achieved by 2030. The upfront cash offer represents a 38% premium to Lantheus' 60-day volume-weighted average price. By acquiring Lantheus, Curium integrates its global theranostics manufacturing footprint with Lantheus' US commercial network and F18-isotope prostate diagnostics franchise, directly expanding treatment availability for hospital providers and oncology patients across 70 countries.

Generic drugmaker Sandoz agreed to pay $478.5 million to resolve claims brought by US states and drug resellers alleging a industry conspiracy to inflate prices and curb competition. Under the primary agreement, Sandoz will pay $400 million over seven years starting in 2027 to settle claims across three pending state cases, alongside $50 million to states from earlier settlements and $28.5 million for indirect reseller class actions. The cash outflow reduces capital available for Sandoz's pipeline investments while providing financial recovery to state healthcare programs and commercial drug distributors previously impacted by generic pricing manipulation.